Pearl River Capital, LLC Repligen Corp Transaction History

Pearl River Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$138.42 - $180.31 $200,293 - $260,908	1,447 New	1,447 $204,000
Q1 2023 Dec 19, 2024	BUY	$154.26 - $198.1 $612,720 - $786,853	3,972 New	3,972 $668,000
Q4 2022 Feb 13, 2023	BUY	$162.42 - $220.56 $25,175 - $34,186	155 Added 4.06%	3,972 $672,000
Q3 2022 Nov 14, 2022	BUY	$160.42 - $256.21 $36,415 - $58,159	227 Added 6.32%	3,817 $714,000
Q2 2022 Aug 12, 2022	BUY	$140.68 - $188.02 $322,297 - $430,753	2,291 Added 176.37%	3,590 $583,000
Q1 2022 May 13, 2022	SELL	$161.19 - $257.96 $140,396 - $224,683	-871 Reduced 40.14%	1,299 $244,000
Q4 2021 Feb 11, 2022	SELL	$247.59 - $304.47 $209,956 - $258,190	-848 Reduced 28.1%	2,170 $575,000
Q3 2021 Nov 12, 2021	BUY	$194.77 - $324.21 $587,815 - $978,465	3,018 New	3,018 $872,000

486

56.5M

251K

458K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $7.21B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.